Novartis, one of the world’s largest pharmaceutical companies, has executed an agreement to sell one of Sandoz Turkey’s manufacturing facilities in Gebze to Generica İlaç, a Turkish company engaged in the manufacturing, marketing and sale of pharmaceutical products since 2007. The transaction includes the transfer of all associated assets and employees of Sandoz Turkey on the Gebze site. The deal is expected to close by mid-2020 subject to obtaining the necessary approvals from regulatory authorities, including the Competition Board, the Gebze Plastic Manufacturers Organized Industrial Zone and the Ministry of Industry and Technology. After closing, Generica İlaç will continue to manufacture and supply certain products to Novartis.
Paksoy is pleased to announce that Elvan Aziz (partner), Nazlı Bezirci (counsel) and Gözde Zorlu (associate) are advising Novartis on this transaction.
Share
Related persons
You can contact us for detailed information.


Legal Information
This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.
You May Be Interested In
16 December 2025
We are recognised as Tier 1 in Dispute Resolution and Tier 2 in Arbitration by Benchmark Litigation in Türkiye
We are recognised as Tier 1 in Dispute Resolution and Tier 2 in Arbitration by Benchmark Litigation in Türkiye.
8 December 2025
We are named Turkey Legal Advisor of the Year at the 2025 Mergermarket European M&A Awards
We are proud to share that we have been named the Turkey Legal Advisor of the Year at the Mergermarket European M&A Awards 2025.
4 December 2025
We are, once again, ranked Highly Recommended in Türkiye in the GCR 100 2026
We are, once again, ranked Highly Recommended in Türkiye in the GCR 100 2026, the global guide recognizing the world’s leading competition…
2 December 2025
Serdar Paksoy Shared Insights in the Anti-Corruption Report Interview
David Hill from the Anti-Corruption Report spoke with Serdar Paksoy about the country’s anti-corruption laws, enforcement and related risks…